Traws Pharma, Inc. is a clinical stage biopharmaceutical company focused on developing novel antiviral therapies for respiratory viral diseases. The company is advancing two investigational oral small molecule antivirals: Ratutrelvir, aimed at treating COVID-19 and Long COVID, and Tivoxavir marboxil, designed for bird flu and seasonal influenza. Traws Pharma targets difficult-to-treat virus strains and employs accelerated clinical trial strategies to ensure safety and effective dosing for vulnerable patient populations.
- Website
- www.trawspharma.com
- Issuer profile
- All listings